In-licensing and out-licensing decisions are important channels for pharmaceutical companies to use in managing their portfolios for growth and balance. In-licensing decisions are often driven by expanding or consolidating a company’s position in a therapy area. Meanwhile, out-licensing decisions are driven more by risk and value trade-offs related to development investment and market access considerations for new products, or by obtaining a performance boost for “tail” mature in-line products.
We support our larger clients by conducting due diligence on in-licensing assets and establishing deal negotiation ranges by identifying “tipping off” and “walkaway” points. We also support emerging innovator companies in out-licensing their assets outright or in developing partnering arrangements with larger companies. Often our support extends to negotiating deal terms and facilitating clients’ partnering decisions. For mature portfolios with extensive tails, we help our clients develop win/win arrangements with partners to out-license or develop profit-sharing arrangements with partners.
We work with clients on these decisions at all stages of asset development and for in-line products.